Filing Details
- Accession Number:
- 0001140361-21-021489
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-06-17 18:45:33
- Reporting Period:
- 2021-06-15
- Accepted Time:
- 2021-06-17 18:45:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1472091 | Pds Biotechnology Corp | PDSB | Pharmaceutical Preparations (2834) | 264231384 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1492710 | Gene Gregory Freitag | C/O Pds Biotechnology Corporation 25B Vreeland Road Florham Park NJ 07932 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-06-15 | 5,882 | $8.50 | 46,153 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2021-06-17 | 9,000 | $0.00 | 9,000 | $9.95 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
9,000 | 2031-06-17 | No | 4 | A | Direct |
Footnotes
- Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on June 17, 2021, and such shares of common stock are subject to a lock up agreement between the Reporting Person and Cantor Fitzgerald & Co., pursuant to which the shares cannot be sold for 90 days following June 15, 2021.
- The Stock Option will vest in full and become fully exercisable on June 17, 2022.